1030 related articles for article (PubMed ID: 31370265)
1. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
2. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
[TBL] [Abstract][Full Text] [Related]
3. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
4. Wnt/β-catenin-activated Ewing sarcoma cells promote the angiogenic switch.
Hawkins AG; Pedersen EA; Treichel S; Temprine K; Sperring C; Read JA; Magnuson B; Chugh R; Lawlor ER
JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32544094
[TBL] [Abstract][Full Text] [Related]
5. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
[TBL] [Abstract][Full Text] [Related]
6. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome.
Tsuda Y; Zhang L; Meyers P; Tap WD; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2020 Sep; 59(9):525-534. PubMed ID: 32362012
[TBL] [Abstract][Full Text] [Related]
7. Advances in the Treatment of Pediatric Bone Sarcomas.
Grohar PJ; Janeway KA; Mase LD; Schiffman JD
Am Soc Clin Oncol Educ Book; 2017; 37():725-735. PubMed ID: 28561686
[TBL] [Abstract][Full Text] [Related]
8. Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions.
Jedlicka P
Int J Clin Exp Pathol; 2010 Mar; 3(4):338-47. PubMed ID: 20490326
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
10. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
11. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
13. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers.
Mitra P; Eckenrode JM; Mandal A; Jha AK; Salem SM; Leggas M; Rohr J
J Med Chem; 2018 Sep; 61(17):8001-8016. PubMed ID: 30114371
[TBL] [Abstract][Full Text] [Related]
14. Wnt signaling in osteosarcoma.
Lin CH; Ji T; Chen CF; Hoang BH
Adv Exp Med Biol; 2014; 804():33-45. PubMed ID: 24924167
[TBL] [Abstract][Full Text] [Related]
15. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS
Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587
[TBL] [Abstract][Full Text] [Related]
16. [Functional genomics of Ewing sarcoma].
Grünewald TGP
Pathologe; 2017 Nov; 38(Suppl 2):198-201. PubMed ID: 28849372
[TBL] [Abstract][Full Text] [Related]
17. Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma.
Yodoya N; Iwamoto S; Matsumine A; Azuma E; Toyoda H; Miura Y; Nakatani K; Imai H; Hirayama M; Komada Y
J Pediatr Hematol Oncol; 2017 Jan; 39(1):6-9. PubMed ID: 27918348
[TBL] [Abstract][Full Text] [Related]
18. Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors.
Tanaka M; Yamazaki Y; Kanno Y; Igarashi K; Aisaki K; Kanno J; Nakamura T
J Clin Invest; 2014 Jul; 124(7):3061-74. PubMed ID: 24911143
[TBL] [Abstract][Full Text] [Related]
19. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
20. Ewing's sarcoma: standard and experimental treatment options.
Subbiah V; Anderson P; Lazar AJ; Burdett E; Raymond K; Ludwig JA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):126-40. PubMed ID: 19533369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]